FAS full analysis set, ins insulin, met metformin, N number of patients included in analyses, OD once daily, RCT randomised controlled trial, SGLT2i sodium-glucose cotransporter-2 inhibitor, SU sulphonylurea, TZD thiazolidinedione a Dose adjustable according to efficacy and safety criteria and investigators clinical judgement b Short-term insulin ( 14 days) was also permitted but is not part of these subgroup analyses The PIONEER trial protocols were approved by institutional review boards or independent ethics committees at the participating trial sites, and the studies were conducted in accordance with ICH Good Clinical Practice guidelines and the Declaration of Helsinki
Additionally, weight loss offers no benefit to a pregnant patient and may cause fetal harm
TRIUMPH-6 (weight maintenance): Active, but no longer recruiting (643 participants enrolled)
How does hydration affect oral BPC-157 absorption
Nevertheless, the overall trend suggests a reduction in basal insulin dose by up to 17% and a decrease in prandial insulin dose by up to 30% in addition of GLP-1RA to insulin therapy, especially with long-acting forms [32]
